A study of AM0010 combined with pembrolizumab in 19 patients with RCC, NSCLC or Melanoma resulted in increased Th1 cytokines and proliferation of PD1+ activated CD8 T-cells while decreasing the proliferation of Tregs in peripheral blood. This evidence concerns the gene CD8A and melanoma.